TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Sponsor: Boston Scientific Corporation · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT05303467 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05303467 Rescue Dossier →